BRCA1 promoter methylation and pathogenic genomic alterations
in homologous recombination and repair (HRR) genes are
mutually exclusive in cancer patients.1-4
Predict Clinical Response
CHARACTERIZE CANCER
Promoter methylation biomarkers can
expand patient reach
or predict response.1,2
PARPi, poly (ADP-ribose) polymerase inhibitor.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
Predict clinical response to DNA-damaging chemotherapy
with blood-based BRCA1 promoter methylation.2